Topical heparins have been used extensively in Britain and Germany and marketed under several brand names. These products are not available in the United States. They have been used in other countries for the treatment of thrombophlebitis and subcutaneous bleeding. Most of these topical heparin preparations contain low-molecular-weight heparin (5000-8000 d), but the standard heparin that is marketed in the United States has a molecular weight of approximately 12000 d. The distribution of molecular weights of commercially available heparins is not perfectly symmetrical. Gel-filtration techniques have shown that these heparins are families of heparin chains.
The purpose of this study was to determine whether the heparin available in the United States has sufficient topical absorption for treatment of superficial phlebitis. To study this question, we selected, as the best model, patients with superficial phlebitis. Such superficial phlebitis is commonly seen in patients with malignancies, especially among those who are treated by intravenous chemotherapy with vesicant drugs.
The major criterion for study entry was superficial phlebitis due to chemotherapy or any other cause. Patients with tissue extravasation of chemotherapy drugs were eligible. Informed consent was obtained from each patient.
All patients had tests for prothrombin time (PT) and partial thromboplastin time (PTT) before and 3 days after starting heparin. Pain, induration, and erythema were observed and measured as necessary. Patients were instructed regarding signs and symptoms of overt and occult bleeding, which were also monitored. Patients were initially seen by a physician and then by a registered nurse.
The heparin ointment was made by using commercially available heparin (25000 IU) in 25 gm of anhydrous lanolin base, mixed by using a mortar and pestle, and given to the patient in a plastic container labeled for external use only. The duration of therapy was usually 7-10 days or until resolution of phlebitis. Fifty-one patients were treated between 1982-1991 (see Table 1 ).
Two patients had spontaneous superficial phlebitis of varicose veins; the other 49 patients had chemicalinduced phlebitis. One of these 49 patients had a drug extravasation of vincristine, and two had drug extravasation of mitomycin. None of these three patients required any surgical debridement. The remaining 46 patients had chemical-induced phlebitis caused by the vesicant effects of the chemotherapy drugs.
The two patients with superficial phlebitis had excellent response, with complete resolution of phlebitis in 10 days and with minimal residual induration (see Table 2 ).
Of the 46 patients with chemicalinduced phlebitis, 40 had total resolution in 1 week; these patients began treatment within 2-3 days of the onset of phlebitis. The six patients who did not respond to treatment began treat- ment I week later. Three patients had phlebitis or tissue inflammation due to extravasation. In one patient who had received vincristine, heparin application was started immediately, and the extravasation was totally resolved in 10 days, without any tissue necrosis or skin ulceration. One patient who had received mitomycin had a break in the dermis that healed without any major cicatrization after application of heparin. The other patient with mitomycin extravasation had phlebitis in the left arm and also in the opposite arm; this patient responded well. However, both patients who were on mitomycin required almost 4-6 weeks of twice-a-day application.
None of the patients had any prolongation of PT or PTT, and no obvious or occult bleeding was evident in any of the patients.
Off study, three patients with stage II decubiti were treated, with excellent response.
Thus, topical heparin used in the regimen we have given has been shown to achieve a good response when applied at the site within 48-72 hours of the onset of phlebitis.
Topical heparin has been used in superficial phlebitis. Mehta et al.
(1) have shown its beneficial effects in a randomized double-blind study. The major effect of the topical heparin had been a localized antithrombotic effect. These investigators have shown, with l25 I-labeled fibrinogen, that the fibrinolysis took place at the site of heparin application and that there was rapid decline in the radioactivity compared with radioactivity at the placebo site.
In experimental modes, Meuleman et al. (2) have shown antithrombotic properties of heparin after topical application, even after obtaining serial skin biopsies.
Thus, topical heparin has been used with proven efficacy in reducing superficial phlebitis and in decreasing local pain, redness, and swellingeven in patients with cellulitis. The use of such heparin cream is safe, effective, and well tolerated. Studies of rodent carcinogenicity have demonstrated 1,3-butadiene to be a potent carcinogen in mice, producing a variety of tumors including lymphocytic lymphoma and hemangiosarcoma of the heart and neoplasms of the lung, forestomach, Harderian gland, preputial gland, liver, mammary gland, and ovary (1-3). Epidemiological studies have consistently shown associations between exposure to 1,3-butadiene and excess mortality due to lymphatic and hematopoietic cancers (4-6). To date, all reports of adequately performed carcinogenicity studies in mice exposed to 1,3-butadiene have shown an increased incidence of tumors. The concentrations studied range from as high as 1250 ppm for 60 weeks (3) to as low as 6.25 ppm for 2 years (6 hours per day for 5 days a week). In addition, exposures to 200 ppm for 40 weeks or 625 ppm for 13 weeks were carcinogenic in mice at the same sites identified in the 2-year study (2).
Although these data can and are being used to promulgate regulations concerning permissible ambient exposure levels for workers, the data do not allow for predictions of risk associated with a catastrophic release of 1,3-butadiene or during a single short, but unavoidable, occupational high-exposure situation. To address this issue, we performed a study in which groups of 60 male and 60 female B6C3F, mice (8-10 weeks old at the beginning of the study) were exposed for a single 2-hour period to concentrations of 0, 1000, 5000, or 10000 ppm 1,3-butadiene. Exposure conditions and methods were similar to those reported in earlier studies (2,3) . The mice were then held for 2 years, at which time they were killed, and tissues and organs examined microscopically (7).
The single exposure to 1,3-butadiene did not affect survival at 2 years. The number of mice surviving in each group of 60 female mice was as follows: 45, 36, 38, and 48 for those receiving 0, 1000, 5000, and 10000 ppm, respectively. In each group of 60 male mice, the number of surviving mice was 28, 34, 44, and 34 for those receiving 0, 1000, 5000, and 10000 ppm, respectively. There were no clear chemical-related effects on body weights throughout the 2-year period. There were no statistically significant increased incidences of neoplastic or nonneoplastic lesions attributed to exposure to 1,3-butadiene. A comparison of numbers of mice with tumors of organs that have shown increases in previous studies is shown in Table 1 .
The one questionable site was the forestomach of male mice, which showed a nonsignificant trend for squamous cell neoplasms (P = .079; logistic regression test). All but one of these neoplasms was a papilloma; one male in the high-dose group had a carcinoma. The historical control incidence of squamous cell neoplasms is 0.74%, with a range of 0%-4%. Thus, the high-dose incidence of 6% exceeded the historical control range. Although the possibility cannot be excluded that these tumors were caused by exposure to 1,3-butadiene, several factors argue against this. Prior studies have shown that male * Incidence values are given as the number of tumor-bearing animals/number of animals examined. Tissues or organs from some mice that died early were not examined due to autolysis. No significant differences in tumor incidence were observed between the control group and any of the exposure groups by life table or logistic regression analyses.
t-= not applicable.
